Image-Guided Ablation Therapies for Extrahepatic Metastases from Hepatocellular Carcinoma: A Review
- PMID: 37509326
- PMCID: PMC10378118
- DOI: 10.3390/cancers15143665
Image-Guided Ablation Therapies for Extrahepatic Metastases from Hepatocellular Carcinoma: A Review
Abstract
The most common sites of extrahepatic metastases from hepatocellular carcinoma (HCC) are the lungs, intra-abdominal lymph nodes, bones, and adrenal glands, in that order. Although systemic therapies are a common treatment for patients with extrahepatic metastases, local ablative therapies for the extrahepatic metastatic lesions can be performed in selected patients. In this article, the literature on image-guided thermal ablation for metastasis to each organ was reviewed to summarize the current evidence. Radiofrequency ablation was the most commonly evaluated technique, and microwave ablation, cryoablation, and percutaneous ethanol injection were also utilized. The local control rate of thermal ablation therapy was relatively favorable, at approximately 70-90% in various organs. The survival outcomes varied among the studies, and several studies reported that the absence of viable intrahepatic lesions was associated with improved survival rates. Since only retrospective data from relatively small studies has been available thus far, more robust studies with prospective designs and larger cohorts are desired to prove the usefulness of thermal ablation for extrahepatic metastases from HCC.
Keywords: ablation therapy; cryoablation; extrahepatic metastases; hepatocellular carcinoma; microwave ablation; percutaneous ethanol injection; radiofrequency ablation.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review.Jpn J Radiol. 2022 Oct;40(10):1024-1034. doi: 10.1007/s11604-022-01302-0. Epub 2022 Jul 2. Jpn J Radiol. 2022. PMID: 35778630 Free PMC article. Review.
-
Ablation for oligometastatic colorectal carcinoma in extrahepatic, extrapulmonary sites.Int J Hyperthermia. 2022;39(1):633-638. doi: 10.1080/02656736.2021.1952318. Int J Hyperthermia. 2022. PMID: 35465801
-
Percutaneous treatment of extrahepatic recurrence of hepatocellular carcinoma.Diagn Interv Imaging. 2016 Nov;97(11):1117-1123. doi: 10.1016/j.diii.2015.11.020. Epub 2016 Apr 29. Diagn Interv Imaging. 2016. PMID: 27138073
-
Effectiveness and safety in radiofrequency ablation of pulmonary metastases from HCC: a five years study.Med Oncol. 2020 Mar 12;37(4):25. doi: 10.1007/s12032-020-01352-2. Med Oncol. 2020. PMID: 32166529
-
Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques.Nat Clin Pract Oncol. 2006 Jun;3(6):315-24. doi: 10.1038/ncponc0512. Nat Clin Pract Oncol. 2006. PMID: 16757969 Review.
Cited by
-
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.Liver Cancer. 2025 Mar 3:1-27. doi: 10.1159/000544976. Online ahead of print. Liver Cancer. 2025. PMID: 40242794 Free PMC article.
-
Ultrasound-guided percutaneous high-frequency irreversible electroporation in porcine livers using four electrode needles: A feasibility and safety study.Cancer Med. 2024 Mar;13(5):e7035. doi: 10.1002/cam4.7035. Cancer Med. 2024. PMID: 38491833 Free PMC article.
References
-
- Uka K., Aikata H., Takaki S., Shirakawa H., Jeong S.C., Yamashina K., Hiramatsu A., Kodama H., Takahashi S., Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J. Gastroenterol. 2007;13:414–420. doi: 10.3748/wjg.v13.i3.414. - DOI - PMC - PubMed
-
- Yi J., Gwak G.Y., Sinn D.H., Kim Y.J., Kim H.N., Choi M.S., Lee J.H., Koh K.C., Paik S.W., Yoo B.C. Screening for extrahepatic metastases by additional staging modalities is required for hepatocellular carcinoma patients beyond modified UICC stage T1. Hepatogastroenterology. 2013;60:328–332. doi: 10.5754/hge12597. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources